FMP
Charles River Laboratories International, Inc.
CRL
NYSE
Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
171.04 USD
4.11 (2.4%)
Rayan Ahmad
4 days ago
Cresco Labs, trading under the symbol CRLBF on the PNK exchange, is a prominent player in the cannabis industry. The company is known for its cultivation, manufacturing, and retail operations across the United States. As Cresco Labs prepares to release its quarterly earnings on March 12, 2025, investors are eager to see how the company has performed financially in the fourth quarter of 2024. Wall Street estimates that Cresco Labs will report an earnings per share (EPS) of -$0.02. This negative ...
Seeking Alpha
Aug 15, 2024
Charles River came in with another set of soft numbers, indicating a period of weaker business ahead for the company. Management is scaling back CapEx into the business and focusing on buybacks, suggesting there's no viable reinvestment opportunities to grow. The intrinsic worth of the business is $215–$223/share under present conditions, in my opinion, warranting a hold.
Zacks Investment Research
Aug 12, 2024
Examine Charles River's (CRL) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.
Seeking Alpha
Aug 10, 2024
Weak biopharma market challenges persist, impacting CRL's revenue and bottom-line growth. Cost streamlining initiatives in place to generate $150 million in annualized cost savings by FY25. Growth projection includes a 3% revenue decline in FY24, with a fair value of $220 per share based on DCF analysis.
Alex Lavoie
Aug 8, 2024
Charles River Laboratories International, Inc. (NYSE:CRL) faced a significant downturn in its stock performance, with a notable 12% drop in intraday trading on a recent Wednesday. This decline was triggered by the company's announcement of an expected decrease in sales for the full fiscal year, deviating from its prior growth forecasts. Despite achieving second-quarter revenue of $1.03 billion, aligning with estimates, and surpassing profit expectations with $94.08 million, the company observed ...
Zacks Investment Research
Aug 7, 2024
Charles River's (CRL) Manufacturing business segments report organic revenue growth, partially offset by lower revenues in the DSA and RMS segments.
Investopedia
Aug 7, 2024
Shares of Charles River Laboratories (CRL) tumbled over 12% in intraday trading Wednesday after the company said it expects to post a decline in sales for the full fiscal year, instead of growth.
Zacks Investment Research
Aug 7, 2024
Charles River Laboratories (CRL) came out with quarterly earnings of $2.80 per share, beating the Zacks Consensus Estimate of $2.39 per share. This compares to earnings of $2.69 per share a year ago.
Zacks Investment Research
Jul 24, 2024
Growth across Microbial Solutions and Biologics Testing and CDMO businesses is likely to have contributed to Charles River's (CRL) Q2 revenues, offset by lower biopharmaceutical demand.
Zacks Investment Research
Jul 9, 2024
Charles River (CRL) signs an agreement with AAVantgarde to produce GMP plasmid DNA for Stargardt's disease program.